Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.

Abstract

Immunogenic cancer therapies, including radiation and hypomethylating agents, such as 5-azacytidine, rely on tumor cell-intrinsic activation of the RNA receptor RIG-I for their synergism with immune checkpoint inhibitors. Possible RIG-I ligands are small nuclear RNA (snRNA) and endogenous retroviral elements (ERV) leaking from the nucleus during programmed cell death.

• Authors: Hendrik Poeck, Alexander Wintges, Sarah Dahl, Florian Bassermann, Tobias Haas, Simon Heidegger
• Journal: European journal of immunology (Eur J Immunol) Vol. 51 Issue 6 Pg. 1531-1534 (06 2021) ISSN: 1521-4141 [Electronic] Germany
• PMID: 33733474 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.

Chemical References

• Immune Checkpoint Inhibitors
• Receptors, Cell Surface
• Robo3 protein, mouse
• Azacitidine

Topics

• Animals
• Azacitidine (therapeutic use)
• Chemoradiotherapy
• Disease Models, Animal
• Drug Synergism
• Humans
• Immune Checkpoint Inhibitors (therapeutic use)
• Immunotherapy (methods)
• Melanoma (immunology, therapy)
• Melanoma, Experimental
• Mice
• Mice, Inbred C57BL
• Receptors, Cell Surface (genetics, metabolism)
• Signal Transduction
• Treatment Outcome